Topic: Good By from ASCO Florida
The GI ASCO is coming to an end today.
As always, it has been a great experience. Foremost I am happy to see that our presence at conferences is always welcome and in some instances even highly anticipated. This was expressed in the many conversations I engaged with the physicians located in the US and those physicians from abroad. Our site is destined to have global reach and impact and certainly, we are well on our way of achieving this goal. Much can be attributed to the discussion group and the very special members on our site who consistently welcome those newly joining and those of you actively engaging in discussions with each other. My wish is for any patient touched by this cancer indiscriminately of where he or she resides, is to become a member of the Cholangiocarcinoma Foundation. This cancer in comparison to some of the better-known cancers such as, breast, or prostrate, etc. is severely lacking in the area of support, understanding, and published information; all things of high importance and readily and plentifully available to patients with one of the cancer of high occurrence. All of us are too well aware of the fact Cholangiocarcinnoma has an enormous impact on our life and that potentially, it can be a very lonely and frightening experience. Thanks to all, we have come a long way.
I will now pack my bags and ready myself for the flight to rainy California.
Best to all,
I am also enclosing something of interest to some and something to possibly discuss with your physician regarding cachexia.
Thalidomide vs. thalidomide with olanziapine and megadtrol acetate in threatment of chaexia in gastrointestinal cancer. A randomized trial.
S.C. Sanchetee, Rajastan Cancer Cure Hopital, Jodhpur, India
Conclusion: Thalidomide with olanzapine and megestrol acetate.
This study demonstrated the effectiveness and was well tolerated by patients experiencing loss of with and lean body mass due to chachexia (weight loss) due to advanced gastrointestinal cancer. Also it provided better quality of life in terminal stage.